Ok. As a clinician who is completely free from either company, I can say that Arestin is a superior product any way you slice it. The chance that Tolmar will take any significant market share from Orapharma is just BS. Look at the research and the sell design. Studies without scaling and root planing? Really? It's as if to say money and sales is the only goal, not patient care or improving treatment outcomes. And if the PI is followed the price difference is virtually non existent! Unmeasured antibiotic and ucontrolled placement can't guarantee that the infected pockets are even being treated effectively! Not to mention that if patient cost, patient care and patient accessibility were of concern, then your company would strive to make the product re-imbursement accessible through medical benefits like OP did!
I'd LOVE to see how you'd 'sell' your product if you actually had to. I've used the whatever FREE toothpaste I get from my office to brush, but when I found myself on vaca with no TP, I bought the superior brand not the cheapest!
